Search research articles
Contact Us
Filters
Showing results (51-60 of 69) with videos related to
Page
of 7
Sort By:
Journal of Medicinal Chemistry
|
August 20, 2010
Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency
Christopher W Murray, Maria G Carr, Owen Callaghan, et al.
The Journal of Experimental Medicine
|
March 30, 2023
Phagocytosis increases an oxidative metabolic and immune suppressive signature in tumor macrophages
Michael A Gonzalez, Daniel R Lu, Maryam Yousefi, et al.
Cell Reports
|
January 14, 2023
A multiplexed in vivo approach to identify driver genes in small cell lung cancer
Myung Chang Lee, Hongchen Cai, Christopher W Murray, et al.
Journal of Medicinal Chemistry
|
January 22, 2005
Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation
Adrian L Gill, Martyn Frederickson, Anne Cleasby, et al.
Cancer Discovery
|
September 23, 2025
EML4-ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Alberto Diaz-Jimenez, Emily G Shuldiner, Kalman Somogyi, et al.
Journal of Medicinal Chemistry
|
November 8, 2007
Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency
Philip D Edwards, Jeffrey S Albert, Mark Sylvester, et al.
Journal of Medicinal Chemistry
|
December 10, 2016
Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>)
Alison J-A Woolford, Philip J Day, Véronique Bénéton, et al.
ACS Medicinal Chemistry Letters
|
July 21, 2015
Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors
Christopher W Murray, Valerio Berdini, Ildiko M Buck, et al.
Cancer Research
|
April 15, 2022
Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities
Maryam Yousefi, Gábor Boross, Carly Weiss, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 3, 2007
Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitors
Jeffry B Franciskovich, John J Masters, Wayne W Weber, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 69) with videos related to
Sort By:
Page
of 7
Journal of Medicinal Chemistry
|
August 20, 2010
Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency
Christopher W Murray, Maria G Carr, Owen Callaghan, et al.
The Journal of Experimental Medicine
|
March 30, 2023
Phagocytosis increases an oxidative metabolic and immune suppressive signature in tumor macrophages
Michael A Gonzalez, Daniel R Lu, Maryam Yousefi, et al.
Cell Reports
|
January 14, 2023
A multiplexed in vivo approach to identify driver genes in small cell lung cancer
Myung Chang Lee, Hongchen Cai, Christopher W Murray, et al.
Journal of Medicinal Chemistry
|
January 22, 2005
Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation
Adrian L Gill, Martyn Frederickson, Anne Cleasby, et al.
Cancer Discovery
|
September 23, 2025
EML4-ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Alberto Diaz-Jimenez, Emily G Shuldiner, Kalman Somogyi, et al.
Journal of Medicinal Chemistry
|
November 8, 2007
Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency
Philip D Edwards, Jeffrey S Albert, Mark Sylvester, et al.
Journal of Medicinal Chemistry
|
December 10, 2016
Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>)
Alison J-A Woolford, Philip J Day, Véronique Bénéton, et al.
ACS Medicinal Chemistry Letters
|
July 21, 2015
Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors
Christopher W Murray, Valerio Berdini, Ildiko M Buck, et al.
Cancer Research
|
April 15, 2022
Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities
Maryam Yousefi, Gábor Boross, Carly Weiss, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 3, 2007
Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitors
Jeffry B Franciskovich, John J Masters, Wayne W Weber, et al.
Page
of 7